• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by AmerisourceBergen Corporation

    2/5/24 4:16:32 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care
    Get the next $ABC alert in real time by email
    FWP 1 tm244434d3_fwp.htm FWP

     

    Filed Pursuant to Rule 433

    Registration No. 333-261306

    February 5, 2024

     

    Cencora, Inc.

     

    $500,000,000 5.125% Senior Notes due 2034

     

    Pricing Term Sheet

     

    Issuer: Cencora, Inc.
    Offering Format: SEC Registered
    Trade Date: February 5, 2024
    Settlement Date: February 7, 2024 (T+2)
    Joint Book-Running Managers:

    BofA Securities, Inc.

    Citigroup Global Markets Inc.

    J.P. Morgan Securities LLC
    Wells Fargo Securities, LLC

    BNP Paribas Securities Corp.

    U.S. Bancorp Investments, Inc.

    Senior Co-Managers:

    Morgan Stanley & Co LLC

    Scotia Capital (USA) Inc.

    TD Securities (USA) LLC

    Co-Managers:

    PNC Capital Markets LLC

    SG Americas Securities, LLC

    MUFG Securities Americas Inc.

    Security Title: 5.125% Senior Notes due 2034
    Principal Amount: $500,000,000
    Coupon: 5.125%
    Maturity Date: February 15, 2034
    Public Offering Price: 99.867% of the principal amount
    Yield to Maturity: 5.142%
    Spread to Benchmark Treasury: 98 basis points
    Benchmark Treasury Issue: 4.500% due November 15, 2033
    Benchmark Treasury Price: 102-22
    Benchmark Treasury Yield: 4.162%

     

     

    Ratings*:

    Baa2 (Stable) (Moody’s) / BBB+ (Stable) (S&P) /

    A- (Stable) (Fitch)

    Interest Payment Dates: February 15 and August 15, beginning August 15, 2024
    Optional Redemption:

    Make-whole call at T+15 basis points

     

    Par call on or after November 15, 2033 (the date that is three months prior to maturity)

    Change of Control Triggering Event Put: 101% of principal amount plus accrued interest to the date of purchase
    CUSIP: 03073E AU9
    ISIN: US03073EAU91

     

    *Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

     

    The issuer has filed an automatic shelf registration statement, including a prospectus dated November 23, 2021 (File No. 333-261306), and a preliminary prospectus supplement dated February 5, 2024 with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling BofA Securities, Inc. toll-free at 1-800-294-1322, Citigroup Global Markets Inc. toll-free at 1-800-831-9146, J.P. Morgan Securities LLC collect at 1-212-834-4533 or Wells Fargo Securities, LLC toll-free at 1-800-645-3751.

     

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

     

     

    Get the next $ABC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABC

    DatePrice TargetRatingAnalyst
    3/31/2023$185.00Buy
    Citigroup
    1/31/2023$185.00Outperform
    Evercore ISI
    10/11/2022$160.00 → $169.00Neutral → Buy
    BofA Securities
    8/22/2022Equal-Weight
    Morgan Stanley
    7/11/2022$150.00Outperform → In-line
    Evercore ISI
    6/7/2022$167.00 → $178.00Hold → Buy
    Deutsche Bank
    5/26/2022Equal Weight → Overweight
    Barclays
    4/12/2022$178.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ABC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Clark Gina sold $253,528 worth of shares (1,100 units at $230.48), decreasing direct ownership by 4% to 24,802 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    2/14/24 4:14:49 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    Nally Dennis M was granted 132 shares, increasing direct ownership by 1% to 9,383 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    2/5/24 4:13:05 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    Baumann Werner was granted 106 shares, increasing direct ownership by 17% to 720 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    2/5/24 4:10:57 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    $ABC
    SEC Filings

    View All

    AmerisourceBergen Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    2/9/24 4:05:35 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    AmerisourceBergen Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    2/7/24 1:48:13 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    SEC Form FWP filed by AmerisourceBergen Corporation

    FWP - Cencora, Inc. (0001140859) (Subject)

    2/5/24 4:16:32 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    $ABC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AmerisourceBergen Elects Werner Baumann and Lauren Tyler to Its Board of Directors

    AmerisourceBergen Corporation (NYSE:ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023. With the election of Mr. Baumann and Ms. Tyler, the Board of Directors will increase from ten to twelve members, ten of whom are independent. "We look forward to welcoming Mr. Baumann and Ms. Tyler to AmerisourceBergen's Board of Directors. Their experience at preeminent multinational companies and unique perspectives will complement our Board's skill sets and help oversee the company's long-term, sustainable growth," said Mark Durcan, Lead Independent Director. "Werner and Lauren's expertise in their

    8/15/23 8:00:00 AM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    Walgreens Boots Alliance Sells Shares of AmerisourceBergen Corporation for $1.85 Billion of Initial Proceeds

    Transaction Highlights Walgreens Boots Alliance announces the sale of shares of AmerisourceBergen Corporation pursuant to prepaid variable share forward transactions executed through a registered public offering for current proceeds of approximately $1.6 billion and, depending on the stock price at the time, potentially additional proceeds at maturity, along with a concurrent share repurchase by AmerisourceBergen of approximately $250 million Prepaid variable share forward transactions provide liquidity while maintaining ability to participate in potential stock price appreciation Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate pur

    8/3/23 6:48:00 PM ET
    $ABC
    $WBA
    Other Pharmaceuticals
    Health Care
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    AmerisourceBergen Announces Registered Public Offering of Common Shares and Common Share Repurchase

    AmerisourceBergen Corporation (NYSE:ABC) (the "Company") announced today a registered public offering of 10.5 million shares of common stock of the Company in connection with Walgreens Boots Alliance Holdings LLC (the "Selling Stockholder") entering into prepaid variable share forward transactions (the "variable forward transactions") relating to the Company's common stock with certain counterparties (the "counterparties"). The Company has been advised that, in order to establish their initial hedge positions with respect to the variable forward transactions, the counterparties or their affiliates will borrow an aggregate of 7,293,548 shares of the Company's common stock from third-party

    8/3/23 4:33:00 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    $ABC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on AmerisourceBergen with a new price target

    Citigroup initiated coverage of AmerisourceBergen with a rating of Buy and set a new price target of $185.00

    3/31/23 7:17:41 AM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    Evercore ISI resumed coverage on AmerisourceBergen with a new price target

    Evercore ISI resumed coverage of AmerisourceBergen with a rating of Outperform and set a new price target of $185.00

    1/31/23 7:07:23 AM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    AmerisourceBergen upgraded by BofA Securities with a new price target

    BofA Securities upgraded AmerisourceBergen from Neutral to Buy and set a new price target of $169.00 from $160.00 previously

    10/11/22 7:14:28 AM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    $ABC
    Financials

    Live finance-specific insights

    View All

    AmerisourceBergen Reports Fiscal 2023 Third Quarter Results

    Revenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92 Adjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023 Company will begin operating as Cencora and trading under the ticker symbol "COR," effective August 30, 2023 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2023 third quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compare

    8/2/23 6:30:00 AM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    AmerisourceBergen Announces Date and Time for Third Quarter Fiscal 2023 Earnings Release

    AmerisourceBergen Corporation (NYSE:ABC) today announced that it plans to release its results for the Third Quarter of Fiscal 2023 on Wednesday, August 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 2, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.amerisourcebergen.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled st

    6/29/23 4:30:00 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    AmerisourceBergen Reports Fiscal 2023 Second Quarter Results

    Revenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50 Adjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2023 second quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to $2.59 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that

    5/2/23 6:30:00 AM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    $ABC
    Leadership Updates

    Live Leadership Updates

    View All

    AmerisourceBergen Announces Quarterly Dividend

    VALLEY FORGE, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors declared a quarterly dividend of $0.44 per common share, payable March 1, 2021, to stockholders of record at the close of business on February 12, 2021. About AmerisourceBergen AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our dail

    1/14/21 4:30:00 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    $ABC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by AmerisourceBergen Corporation

    SC 13G - Cencora, Inc. (0001140859) (Subject)

    2/14/24 10:02:59 AM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by AmerisourceBergen Corporation (Amendment)

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    2/13/24 5:00:59 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by AmerisourceBergen Corporation (Amendment)

    SC 13G/A - AMERISOURCEBERGEN CORP (0001140859) (Subject)

    1/10/23 12:37:35 PM ET
    $ABC
    Other Pharmaceuticals
    Health Care